Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive decline and offer a more precise framework for clinical intervention in Alzheimer's disease.
The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

This review synthesizes recent large-scale genomic evidence (ROPAD, PD GENEration, MDSGene) to outline the diagnostic yield, ethnic variations, and genotype-phenotype correlations in Parkinson’s disease, emphasizing the transition toward universal genetic testing for clinical trial stratification.
Dynamic Phenotyping in ARDS: AI-Driven Insights Reveal Why Corticosteroid Benefits Depend on Inflammatory State

Dynamic Phenotyping in ARDS: AI-Driven Insights Reveal Why Corticosteroid Benefits Depend on Inflammatory State

A groundbreaking study utilizing an AI classifier demonstrates that ARDS inflammatory phenotypes are dynamic and dictate corticosteroid efficacy. While hyperinflammatory patients benefit from steroids, hypoinflammatory patients face increased mortality, necessitating real-time phenotypic monitoring to optimize critical care interventions.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.

Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups

A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to optimize performance in different populations.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.